Targeting KIT with imatinib has demonstrated remarkable efficacy in patients with gastrointestinal stromal tumors (GIST), but initial trials in melanoma were unsuccessful, clearly due to the absence of selection of patients with aberrations in KIT [69-71]. Here, KIT is linked to gastrointestinal stromal tumor.